Genetic Features of Aflatoxin-Associated Hepatocellular Carcinoma

Gastroenterology

Volumn 153, Issue 1, 2017, Pages 249-262.e2

  Zhang, Weilong ^a   He, Huan ^b   Zang, Mengya ^b   Wu, Qifeng ^b   Zhao, Hong ^b   Lu, Ling ling ^c   Ma, Peiqing ^b   Zheng, Hongwei ^c   Wang, Nengjin ^c   Zhang, Ying ^b   He, Siyuan ^b   Chen, Xiaoyan ^b   Wu, Zhiyuan ^b   Wang, Xiaoyue ^d   Cai, Jianqiang ^b   Liu, Zhihua ^b   Sun, Zongtang ^b   Zeng, Yi Xin ^e   Qu, Chunfeng ^f   Jiao, Yuchen ^b  

^a PEKING UNIVERSITY   (China)

^b CANCER HOSPITAL   (China)

^c QIDONG LIVER CANCER INSTITUTE   (China)

^d INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^e SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^f PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Aspergillus; Liver Cancer; Pathogenesis; Risk Factor

Indexed keywords

AFLATOXIN; ANTIGEN; CD34 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; ANGIOGENIC PROTEIN; BAI1 PROTEIN, HUMAN; CARCINOGEN; PROTEIN P53;

ADGRB1 GENE; ARTICLE; CAPILLARY DENSITY; CHINA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FRANCE; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPAN; LIVER CELL CARCINOMA; LYMPHOCYTIC INFILTRATION; MISSENSE MUTATION; MUTATION RATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR GENE; SANGER SEQUENCING; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; UNITED STATES; WHOLE GENOME SEQUENCING; CHEMICALLY INDUCED; CHEMISTRY; DNA MUTATIONAL ANALYSIS; EXOME; GENETICS; LIVER TUMOR; MICROVASCULATURE; MUTATION; TUMOR ASSOCIATED LEUKOCYTE; VASCULARIZATION;

AFLATOXINS; ANGIOGENIC PROTEINS; ANTIGENS, CD34; B7-H1 ANTIGEN; CARCINOGENS; CARCINOMA, HEPATOCELLULAR; DNA MUTATIONAL ANALYSIS; EXOME; HUMANS; LIVER NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MICROVESSELS; MUTATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85020903657     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2017.03.024     Document Type: Article

References (45)

1. Jemal, A., Bray, F., Center, M.M., et al. Global cancer statistics. CA Cancer J Clin 61 (2011), 69–90.
2. Poon, D., Anderson, B.O., Chen, L.T., et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 10 (2009), 1111–1118.
3. Lopez, C., Ramos, L., Bulacio, L., et al. Aflatoxin B1 content in patients with hepatic diseases. Medicina (B Aires) 62 (2002), 313–316.
4. Williams, J.H., Phillips, T.D., Jolly, P.E., et al. Human aflatoxicosis in developing countries: a review of toxicology, exposure, potential health consequences, and interventions. Am J Clin Nutr 80 (2004), 1106–1122.
5. Kensler, T.W., Qian, G.S., Chen, J.G., et al. Translational strategies for cancer prevention in liver. Nat Rev Cancer 3 (2003), 321–329.
6. Kensler, T.W., Roebuck, B.D., Wogan, G.N., et al. Aflatoxin: a 50-year odyssey of mechanistic and translational toxicology. Toxicol Sci 120:Suppl 1 (2011), S28–S48.
7. Sun, Z., Chen, T., Thorgeirsson, S.S., et al. Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China. Carcinogenesis 34 (2013), 1800–1805.
8. Likun Z. Million tons of swill-cooked oil back on table. http://www.chinadaily.com.cn/china/2010-03/18/content_9610919.htm. Published 2010. Accessed May 8, 2015.
9. Meier, B., Cooke, S.L., Weiss, J., et al. C. elegans whole-genome sequencing reveals mutational signatures related to carcinogens and DNA repair deficiency. Genome Res 24 (2014), 1624–1636.
10. Hsu, I.C., Metcalf, R.A., Sun, T., et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350 (1991), 427–428.
11. Bressac, B., Kew, M., Wands, J., et al. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350 (1991), 429–431.
12. Ming, L., Thorgeirsson, S.S., Gail, M.H., et al. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology 36 (2002), 1214–1220.
13. Chin, L., Meyerson, M., Aldape, K., et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 (2008), 1061–1068.
14. Hudson, T.J., Anderson, W., Aretz, A., et al. International network of cancer genome projects. Nature 464 (2010), 993–998.
15. Li, H., Durbin, R., Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26 (2010), 589–595.
16. Cibulskis, K., Lawrence, M.S., Carter, S.L., et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 31 (2013), 213–219.
17. Koboldt, D.C., Zhang, Q., Larson, D.E., et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 22 (2012), 568–576.
18. Wang, Q., Jia, P., Zhao, Z., VirusFinder: software for efficient and accurate detection of viruses and their integration sites in host genomes through next generation sequencing data. PLoS One, 8, 2013, e64465.
19. Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., et al. Deciphering signatures of mutational processes operative in human cancer. Cell Rep 3 (2013), 246–259.
20. Alexandrov, L.B., Signatures of mutational processes in human cancer. Nature 500 (2013), 415–421.
21. Xue, Y., Lim, S., Brakenhielm, E., et al. Adipose angiogenesis: quantitative methods to study microvessel growth, regression and remodeling in vivo. Nat Protoc 5 (2010), 912–920.
22. Hoffman, M.M., Ernst, J., Wilder, S.P., et al. Integrative annotation of chromatin elements from ENCODE data. Nucl Acids Res 41 (2013), 827–841.
23. Katainen, R., Dave, K., Pitkanen, E., et al. CTCF/cohesin-binding sites are frequently mutated in cancer. Nat Genet 47 (2015), 818–821.
24. Nikolaev, S.I., Rimoldi, D., Iseli, C., et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet 44 (2012), 133–139.
25. Govindan, R., Ding, L., Griffith, M., et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150 (2012), 1121–1134.
26. Zang, Z.J., Cutcutache, I., Poon, S.L., et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 44 (2012), 570–574.
27. Pleasance, E.D., Cheetham, R.K., Stephens, P.J., et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463 (2010), 191–196.
28. Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., et al. Signatures of mutational processes in human cancer. Nature 500 (2013), 415–421.
29. Hoang, M.L., Chen, C.H., Sidorenko, V.S., et al. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci Transl Med, 5, 2013, 197ra102.
30. Poon, S.L., Pang, S.-T., McPherson, J.R., et al. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci Transl Med, 5, 2013, 197ra101.
31. Forbes, S.A., Beare, D., Gunasekaran, P., et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucl Acids Res 43 (2015), D805–D811.
32. Killela, P.J., TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 110 (2013), 6021–6026.
33. Kan, Z., Jaiswal, B.S., Stinson, J., et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466 (2010), 869–873.
34. Cork, S.M., Van Meir, E.G., Emerging roles for the BAI1 protein family in the regulation of phagocytosis, synaptogenesis, neurovasculature, and tumor development. J Mol Med (Berl) 89 (2011), 743–752.
35. Liu, Y., Chang, C.C., Marsh, G.M., et al. Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. Eur J Cancer 48 (2012), 2125–2136.
36. Schulze, K., Imbeaud, S., Letouze, E., et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 47 (2015), 505–511.
37. Liu, Y., Wu, F., Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect 118 (2010), 818–824.
38. Stephenson, J.R., Purcell, R.H., Hall, R.A., The BAI subfamily of adhesion GPCRs: synaptic regulation and beyond. Trends Pharmacol Sci 35 (2014), 208–215.
39. Nishimori, H., Shiratsuchi, T., Urano, T., et al. A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis. Oncogene 15 (1997), 2145–2150.
40. Kaur, B., Cork, S.M., Sandberg, E.M., et al. Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. Cancer Res 69 (2009), 1212–1220.
41. de Fraipont, F., Nicholson, A.C., Feige, J.J., et al. Thrombospondins and tumor angiogenesis. Trends Mol Med 7 (2001), 401–407.
42. Su, A.I., Wiltshire, T., Batalov, S., et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A 101 (2004), 6062–6067.
43. Teschke, R., Traditional Chinese medicine induced liver injury. J Clin Transl Hepatol 2 (2014), 80–94.
44. Rizvi, N.A., Hellmann, M.D., Snyder, A., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
45. Alsuliman, A., Colak, D., Al-Harazi, O., et al. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells. Mol Cancer, 14, 2015.